Albert Baldwin Jr., Ph.D. Kevan Shokat, Ph.D.  William Weiss, M.D., Ph.D.
University of North Carolina, Chapel Hill  University of California, San Francisco University of California, San Francisco


How scientists from two leading research institutes are combining their expertise to better understand and defeat glioblastoma. 

The Goals:

The goals of the research conducted by Drs. Baldwin, Shokat and Weiss are to identify signaling pathways in glioblastoma that function in the growth, survival and promotion of the tumor-initiating cell phenotype, and to target these pathways pharmacologically.

Methodology and Key Findings:

Their focus is on glioblastoma given the dismal prognosis associated with this disease and based on the experience, collaborative interactions, and clinical expertise within the Weiss, Shokat and Baldwin team. Drs. Weiss and Shokat are studying a novel, brain penetrant mTORC1 inhibitor relative to therapeutic effects in glioma models. Drs. Weiss and Baldwin are studying the important NF-κB signaling pathway in glioma, relative to its ability to drive glioma tumor growth. Drs. Weiss and Baldwin are also analyzing interrelated effects of two key signaling pathways, STAT3 and NF-κB, in glioma.

Drs. Weiss, Shokat and Baldwin are studying TAK1 as a key signaling effector in glioma, with the goals of testing TAK1 inhibitors in glioma models. 


Donate to our brain cancer research program here.

The Samuel Waxman Cancer Research Foundation is a 501(c)(3) tax-exempt nonprofit organization. EIN # 13-3020943